EN 简
search
EN 简

Press Release

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus
10 April, 2023
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients
30 March, 2023
JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma
08 March, 2023
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
28 February, 2023
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
12 December, 2022
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients
09 November, 2022
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
27 October, 2022
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
10 October, 2022
JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
04 July, 2022
JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting
05 June, 2022
JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting
09 May, 2022
JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients
25 April, 2022
JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
20 April, 2022
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
03 April, 2022
JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma
31 March, 2022
JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
27 February, 2022
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building
10 January, 2022
JW Therapeutics Presents Primary Clinical Response on Carteyva® (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting
13 December, 2021
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
27 September, 2021
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
26 September, 2021
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
06 September, 2021
JW Therapeutics Announces 2021 Interim Results
27 August, 2021
JW Therapeutics Announces Strategic Partnership with MediTrust Health
20 August, 2021
JW Therapeutics Announces 2020 Annual Results
26 March, 2021
JW Therapeutics and Thermo Fisher Scientific Announce CAR-T Partnership in China
03 February, 2021
JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting
07 December, 2020
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX
03 November, 2020
JW Therapeutics and Lyell Immunopharma Announce Collaboration to Advance Solid Tumor Treatment in China
10 August, 2020
JW Acquires Syracuse Biopharma
20 July, 2020
JW Therapeutics Completes $ 100 Million Series B Financing
09 June, 2020
JW Therapeutics announced the grand opening of R&D center in Zhangjiang Science City of Pudong New Area, Shanghai
12 December, 2018
JW Therapeutics to Build Its First Commercial CAR-T Cell Manufacturing Plant in Suzhou, China
10 August, 2018
JW Therapeutics Closes $ 90 Million Series A Financing
08 March, 2018